---
document_datetime: 2023-09-21 19:50:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/myocet-epar-procedural-steps-taken-authorisation_en.pdf
document_name: myocet-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.9131738
conversion_datetime: 2025-12-19 21:56:51.877851
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company The Liposome Company Ltd. submitted on 1 July 1999 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Evacet, through  the  centralised  procedure.  During  the  procedure  the  name  was  changed  to  Myocet.  After agreement by the CPMP on 24 June 1998, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

| Prof. B. Odlind          | Prof. R. Gaspar (from 25 March 1999 1 January 2000) Prof. Guimar√£es 2000)   |
|--------------------------|-----------------------------------------------------------------------------|
| (from 25 March 1999 to 1 | to                                                                          |
| December 1999)           |                                                                             |
| P. Nilsson               | Morais                                                                      |
| Dr.                      |                                                                             |
| (from 1 December 1999)   | (from 1 January                                                             |

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- During the meeting on 20-22 April 1999 the CPMP considered the proposed trade name Evacet not acceptable.
- The procedure started on 30 July 1999.
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  8  October 1999. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 14 October 1999.
- During  the  meeting  on  16-18  November  1999  the  CPMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the company on 19 November 1999.
- The applicant submitted the responses to the CPMP consolidated list of questions on 7 February 2000.
- The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  site  between  12-14 January 2000 was issued on 9 February 2000.
- In  view  of  the  objection  to  the  trade  name  Evacet,  the  applicant  proposed  the  trade  name Myocet on 10 March 2000.
- The Rapporteur circulated the response assessment report on the company's responses to the list of questions to all CPMP Members on 21 March 2000.
- The Applicant submitted on 12 April 2000 a letter of undertaking as requested by the CPMP' confirming compliance with Follow-up Measures.
- During the meeting on 11-12 April 2000 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Myocet on 12 April 2000.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 13 July 2000.